Cagrilintide vs Retatrutide
Updated 10 sources
Key differences
- 1Retatrutide 12 mg reached 24.2% at 48 weeks in phase 2. Cagrilintide alone reached 10.8% at 4.5 mg over 26 weeks. These are separate trials; there is no head-to-head.
- 2Retatrutide hits GLP-1, GIP and glucagon receptors; cagrilintide hits amylin receptors, which is why people stack them.
- 3Cagrilintide is an amylin analogue. Retatrutide works through GLP-1, GIP and glucagon, with no amylin action.
- 4Cagrilintide is mostly used with semaglutide (CagriSema), which gave 20.4% loss at 68 weeks in REDEFINE 1.
- 5People stack the two because they hit different fullness pathways. That pair is untested.
Side by side
Facts from each record, in the same words as their own pages.
| Cagrilintide | Retatrutide | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
10 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study6
- Jastreboff et al. Retatrutide phase 2 (NEJM 2023)PubMed · checked Oct 23, 2026
- Lau et al. Once-weekly cagrilintide for weight management: phase 2 (Lancet 2021)PubMed · checked Oct 23, 2026
- Garvey et al. Coadministered cagrilintide and semaglutide (REDEFINE 1, NEJM 2025)New England Journal of Medicine · checked Oct 23, 2026
- Enebo et al. Cagrilintide with semaglutide 2.4 mg: phase 1b (Lancet 2021)PubMed · checked Oct 23, 2026
Regulatory4
- CagriSema did not meet primary end point of noninferiority to tirzepatideDrug Topics · checked Oct 23, 2026
- Novo Nordisk submits NDA to FDA for CagriSemaPharmExec · checked Oct 23, 2026
- Retatrutide Meets Phase 3 Weight Loss Endpoints in 2 Obesity TrialsHCPLive · checked Oct 23, 2026
- Eli Lilly offers new weight loss drug to some patients before FDA approvalFOX6 News · checked Oct 23, 2026